<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common" xmlns:g="http://xml.ms.com/ns/itlnc/filelink/US13GFiling/v1.0">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber/>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0000895421</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0000034956</issuerCik>
        <issuerName>TENAX THERAPEUTICS, INC.</issuerName>
        <issuerCusips>
		<issuerCusipNumber>88032L605</issuerCusipNumber>
	  </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>101 GLEN LENNOX DRIVE</com:street1>
          <com:street2>SUITE 300</com:street2>
          <com:city>CHAPEL HILL</com:city>
          <com:stateOrCountry>NC</com:stateOrCountry>
          <com:zipCode>27517</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Morgan Stanley</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>592504</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>596564</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>596564</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.5</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Morgan Stanley Capital Services LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>583297</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>583297</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>583297</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>3.4</classPercent>
      <typeOfReportingPerson>BD</typeOfReportingPerson>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>As of the date hereof, Morgan Stanley Capital Services LLC has ceased to be the beneficial owner of more than five percent of the class of securities.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>TENAX THERAPEUTICS, INC.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, NC, 27517</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>1: Morgan Stanley 2: Morgan Stanley Capital Services LLC</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036</principalBusinessOfficeOrResidenceAddress>
        <citizenship>1: Delaware 2: Delaware</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>BD</typeOfPersonFiling>
        <typeOfPersonFiling>HC</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See the response(s) to Item 9 on the attached cover page(s).</amountBeneficiallyOwned>
        <classPercent>3.5</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See the response(s) to Item 5 on the attached cover page(s).</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See the response(s) to Item 6 on the attached cover page(s).</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See the response(s) to Item 7 on the attached cover page(s).</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See the response(s) to Item 8 on the attached cover page(s).</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>See Exhibit 99.2</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

					*  In Accordance with the Securities and Exchange Commission Release
					No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the
					securities beneficially owned, or that may be deemed to be beneficially owned,
					by certain operating units (collectively, the "MS Reporting Units") of Morgan
					Stanley and its subsidiaries and affiliates (collectively, "MS").  This filing
					does not reflect securities, if any, beneficially owned by any operating units
					of MS whose ownership of securities is disaggregated from that of the MS
					Reporting Units in accordance with the Release.
					</certifications>
      </item10>
    </items>
    <exhibitInfo>

					EXHIBIT NO.                         EXHIBITS
					------------------         ------------------------------------

					99.1                       Joint Filing Agreement

					99.2                       Item 7 Information

					*  Attention. Intentional misstatements or omissions of fact constitute federal
					criminal violations (see 18 U.S.C. 1001).
				</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Morgan Stanley</reportingPersonName>
      <signatureDetails>
        <signature>Claire Gordon</signature>
        <title>Authorized Signatory, Morgan Stanley</title>
        <date>04/08/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Morgan Stanley Capital Services LLC</reportingPersonName>
      <signatureDetails>
        <signature>Claire Gordon</signature>
        <title>Authorized Signatory, Morgan Stanley Capital Services LLC</title>
        <date>04/08/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
